These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8917400)

  • 1. Prediction of the optimum clinical dosing schedule for menogaril from results with tumor-bearing mice.
    Yoshida M; Kobunai T; Nakano K; Saito H; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(5A):2869-73. PubMed ID: 8917400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
    Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
    Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [TUT-7 phase I clinical study. TUT-7 Study Group].
    Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Nakao I; Ota K; Hattori T; Sugimachi K
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1125-33. PubMed ID: 9239166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
    Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
    Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
    Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
    Würthwein G; Boos J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):303-8. PubMed ID: 11914910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose optimization of anthracyclines.
    de Valeriola D
    Anticancer Res; 1994; 14(6A):2307-13. PubMed ID: 7825964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
    Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
    Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
    Weiss GR; Brown TD; Kuhn JG; Von Hoff DD; Earhart RH; Adams WJ; Brewer JE; Hosley JD; Kasunic DA
    Invest New Drugs; 1993 Feb; 11(1):17-27. PubMed ID: 8349432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
    Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
    Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.